Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of patients 12 years of age and older with advanced thyroid cancer with a RET alteration.
Selpercatinib is recommended as an option for treating:
- Advanced RET fusion positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate)
- Advanced RET mutant medullary thyroid cancer
Selpercatinib is recommended only if the cancer has not been treated with a targeted cancer medicine and Eli Lilly provides it according to the commercial arrangement.
